Role of left ventricular diastolic function in ensuringthe energy tissue metabolism in patients with hypertrophiccardiomyopathy
Authors:
Company: A.N. Bakoulev Scientific Center for Cardiovascular Surgery of Ministry of Health of the Russian Federation; Rublevskoe shosse, 135, Moscow, 121552, Russian Federation
For correspondence: Sign in or register.
Type: Cardiomyopathy
DOI:
For citation: Koloskova N.N., Kupryashov A.A., Plyushch M.G. et al. Role of left ventricular diastolic function in ensuring the energy tissue metabolism in patients with hypertrophic cardiomyopathy. Kreativnaya Kardiologiya. 2016; 10 (2): 161-170 (in Russian)
Keywords: hypertrophic cardiomyopathy left ventricular stiffness heart failure with preserved ejection fraction diastolic function cardiopulmonary exercise testing
Abstract
Introduction. Reduced exercise tolerance in patients with hypertrophic cardiomyopathy (HCM) is due to impaired left ventricular myocardial stiffness and diastolic heart failure.
Objective. To investigate the hemodynamic parameters, peak VO2, morpho-functional left ventricular performance, natriuretic peptide level to assess the severity of diastolic dysfunction in patients with hypertrophic cardiomyopathy.
Material and methods. The study included 25 patients (mean age 34.5±15.6 years). Patients were divided into 2 groups, based on the basal interventricular septum thickness and the LV posterior wall thickness ratio. Groups differed significantly at relative increment of end-diastolic LV pressure after Valsalva probe (1.48±0.32 in group 1 vs 1.82±0.45 in the group 2, p=0.041). Patients of the first group with slight increment observed the lowest values of oxygen consumption at rest (ρ=0.517, p=0.07).
Conclusion. It was revealed that diastolic dysfunction in patients with HCM is determined by various functional and morphological factors that can affect the physical activity of patients and prognosis of the disease to varying degree.
References
- Pravin M.S. Hypertrophic cardiomyopathy and diastolic dysfunction. J. Am. Coll. Cardiol. 2003; 42 (2): 286–93.
- Senni M., Paulus W.J., Gavazzi A., Fraser A.G., Diez J. et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur. Heart J. 2014; 35: 2797–811.
- Mishchenko T.A. Left ventricular structure and function in patients with chronic heart failure and obstructive sleep apnea/ hypopnea syndrome. Lechebnoe delo. 2016; 1: 40–7.
- Lang R.M., Badano L.P., Mor-Avi V., Afilalo J., Armstrong A., Ernande L. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 2015; 28 (1): 1–39.
- Komissarova S.M., Ustinova I.B., Sevruk I.V., Kras'ko O.V., Mrochek A.G. Factors associated with progression of chronic heart failure in patients with hypertrophic cardiomyopathy. Serdechnaya nedostatochnost'. 2014; 6: 347–54 (in Russian).
- Kino A., Carr J., Bonow R., Choudhury L. Association of left ventricular wall thickness and myocardial fibrosis/ scar with adverse events in hypertrophic cardiomyopathy: interaction of maximal wall thickness and late gadolinium enhancement by cardiac magnetic resonance. J. Am. Coll. Cardiol. 2012; 59 (13) (Suppl.): E1230.
- Santos-Gallego C.G., Vahl T., Goliasch G., Pazos E.P., Ramachandran S., Sengupta P., Narula J., Fuster V. Diffuse interstitial myocardial fibrosis detected by t1 mapping is increased in hypertrophic cardiomyopathy patients and correlates with left ventricular systolic and diastolic dysfunction. J. Am. Coll. Cardiol. 2013; 61 (10): E1064.
- Sorajja P., Allison T., Hayes C., Nishimura R.A., Lam C.S., Ommen S.R. Prognostic utility of metabolic exercise testing in minimally symptomatic patients with obstructive hypertrophic cardiomyopathy. Am. J. Cardiol. 2012; 109: 1494–502.
- Le V.V., Perez M.V., Wheeler M.T., Myers J., Schnittger I., Ashley E.A. Mechanisms of exercise intolerance in patients with hypertrophic cardiomyopathy. Am. Heart. J. 2009; 158: 27–34.
- Tan Y. T., Wenzelburger F., Lee E. The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion. J. Am. Coll. Cardiol. 2009; 54 (1): 36–46.
- Sinning D., Kasner M., Westermann D., Schulze K., Schultheiss H.P., Tschöpe C. Increased left ventricular stiffness impairs exercise capacity in patients with heart failure symptoms despite normal left ventricular ejection fraction. Cardiol. Res. Pract. Vol. 2011; 1–11.
- Ellims A.H., Iles L.M., Ling L., Hare J.L., Kaye D.M., Taylor A.J. Diffuse myocardial fibrosis in hypertrophic cardiomyopathy can be identified by cardiovascular magnetic resonance, and is associated with left ventricular diastolic dysfunction. J. Cardiovasc. Magn. Reson. 2012; 14 (1): 76–84.
- Poteshkina N.G., Demkina A.E., Krylova N.S., Kovalevskaya E.A. Left ventricular diastolic dysfunction and its pharmaceutical correction with antagonists of the renin-angiotensinaldosterone system in patients with hypertrophic cardiomyopathy. Serdechnaya nedostatochnost'. 2016; 1: 41–6. DOI: 10.18087/rhfj.2016.1.2180 (in Russian).
- Tan Y.T., Wenzelburger F., Lee E. The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion. J. Am. Coll. Cardiol. 2009; 54 (1): 36–46.
- Watanabe S., Shite J., Takaoka H., Shinke T., Imuro Y., Ozawa T. et al. Myocardial stiffness is an important determinant of the plasma brain natriuretic peptide concentration in patients with both diastolic and systolic heart failure. Eur. Heart J. 2006; 27: 832–8.
- Binder J., Ommen S.R., Chen H.H., Ackerman M.J., Tajik A.J., Jaffe A.S. Usefulness of brain natriuretic peptide levels in the clinical evaluation of patients with hypertrophic cardiomyopathy. Am. J. Cardiol. 2007; 100: 712–4.
- Kaski J.P., Tome-Esteban M.T., Mead-Regan S. B-type natriuretic peptide predicts disease severity in children with hypertrophic cardiomyopathy. Heart. 2008; 94: 1307–11.
- Kim S.W., Park S.W., Lim S.H. Amount of left ventricular hypertrophy determines the plasma N-terminal pro-brain natriuretic peptide level in patients with hypertrophic cardiomyopathy and normal left ventricular ejection fraction. Clin. Cardiol. 2006; 29: 155–60.
- Jeffrey B.G., Paul M.M., Steve R.O., Paul S. BNP and survival in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2013; 61 (24): 2456–60.
- Ommen S.R., Nishimura R.A., Appleton C.P., Miller F.A., Oh J.K., Redfield M.M., Tajik A.J. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation. 2000; 102: 1788–94.
- Grewal J., McKelvie R., Lonn E., Tait P., Carlsson J., Gianni M. et al. Brain natriuretic peptide and NT-proBNP predict echocardiographic severity of diastolic dysfunction. Eur. J. Heart Fail. 2008; 10: 252–9.
- Ohtani T., Mohammed S.F., Yamamoto K., Dunlay S.M., Weston S.A., Sakata Y. et al. Diastolic stiffness as assessed by diastolic wall strain is associated with adverse remodelling and poor outcomes in heart failure with preserved ejection fraction. Eur. Heart J. 2012; 33 (14): 1742–9.
About Authors
- Koloskova Nadezhda Nikolaevna, MD, PhD, Cardiologist;
- Kupryashov Aleksey Anatol'evich, MD, DM, Chief of Chair;
- Plyushch Marina Grigor'evna, PhD of Biol. Sci., Chief of Laboratory;
- Berseneva Marina Ivanovana, MD, PhD, Cardiologist, Senior Research Associate;
- Bockeria Leo Antonovich, Academician of Russian Academy of Sciences and Russian Academy of Medical Sciences, Director of A.N. Bakoulev Scientific Center for Cardiovascular Surgery